Literature DB >> 16796375

Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice.

Lakkireddy Harivardhan Reddy1, Jawahar Singh Adhikari, Bilikere Srinirasa Rao Dwarakanath, Rakesh Kumar Sharma, Rayasa Ramachandra Murthy.   

Abstract

The tumoricidal effects of etoposide incorporated into lipid nanoparticles after single-dose administration were investigated in Dalton's lymphoma ascites bearing mice. Etoposide and its nanoparticle formulations were administered intraperitoneally, and the cell cycle perturbation, cytogenetic damage, cell death (apoptosis), tumor regression, and animal survival were investigated as parameters of response with time. The tumor burden of mice treated with etoposide and its nanoparticle formulations decreased significantly (P < .001) compared with the initial up to 4 to 6 days, followed by an increase at later time intervals. Of the 3 different formulations, the survival time of mice was higher when treated with etoposide-loaded tripalmitin (ETP) nanoparticles, followed by etoposide-loaded glycerol monostearate (EGMS) (27.3%) and etoposide-loaded glycerol distearate (EGDS) (27.3%) compared with free etoposide. Cell cycle analysis revealed the hypodiploid peak (sub G0/G1 cell population) as well as G2 arrest in mice treated with etoposide and its nanoparticle formulations. The frequency of dead cells treated with the nanoparticle formulations remained high even after 8 days of treatment compared with free etoposide. The mice treated with nanoparticle formulations exhibited hypodiploid peaks and reduced S phase even 8 days after treatment, whereas the free etoposide-treated mice showed decrease in apoptosis after 3 days of treatment. The apoptotic frequency in cells 17 days after treatment was in the order of ETP > EGMS > EGDS > etoposide. The experimental results indicated that among the 3 nanoparticle formulations studied, the ETP nanoparticles showed greater and prolonged apoptotic induction properties, resulting in the higher increase in survival time of tumor bearing mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16796375      PMCID: PMC3231564          DOI: 10.1007/bf02854895

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  23 in total

1.  Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization.

Authors:  C Schwarz; W Mehnert
Journal:  J Microencapsul       Date:  1999 Mar-Apr       Impact factor: 3.142

Review 2.  Solid lipid nanoparticles: production, characterization and applications.

Authors:  W Mehnert; K Mäder
Journal:  Adv Drug Deliv Rev       Date:  2001-04-25       Impact factor: 15.470

3.  Response of recurrent medulloblastoma to low-dose oral etoposide.

Authors:  D M Ashley; L Meier; T Kerby; F M Zalduondo; H S Friedman; A Gajjar; L Kun; P K Duffner; S Smith; D Longee
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

4.  A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry.

Authors:  J Gong; F Traganos; Z Darzynkiewicz
Journal:  Anal Biochem       Date:  1994-05-01       Impact factor: 3.365

5.  Hematoporphyrin derivatives potentiate the radiosensitizing effects of 2-deoxy-D-glucose in cancer cells.

Authors:  B S Dwarakanath; J S Adhikari; V Jain
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-03-15       Impact factor: 7.038

6.  Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN).

Authors: 
Journal:  Int J Pharm       Date:  1997-11-28       Impact factor: 5.875

7.  Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice.

Authors:  Takashi Tamura; Fumiko Fujita; Masahiko Tanimoto; Masako Koike; Akira Suzuki; Masahide Fujita; Yuji Horikiri; Yasuo Sakamoto; Takehiko Suzuki; Hiroyuki Yoshino
Journal:  J Control Release       Date:  2002-04-23       Impact factor: 9.776

8.  Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study.

Authors:  T Fujimura; Y Yonemura; K Muraoka; H Takamura; Y Hirono; H Sahara; I Ninomiya; H Matsumoto; K Tsugawa; G Nishimura
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

9.  [Toxic reduction and superior therapeutic effects on peritoneal carcinomatosis of etoposide particles suspended in oil in mice].

Authors:  M Lee; T Takahashi; A Hagiwara; A Iwamoto; M Shimotuma; C Yoneyama; M Itoh; T Sasabe; C Sakakura; S Shobayashi
Journal:  Gan To Kagaku Ryoho       Date:  1991-08

10.  Radiation-induced apoptotic cell death in human gastric epithelial tumour cells; correlation between mitotic death and apoptosis.

Authors:  K Yanagihara; M Nii; M Numoto; K Kamiya; H Tauchi; S Sawada; T Seito
Journal:  Int J Radiat Biol       Date:  1995-06       Impact factor: 2.694

View more
  7 in total

1.  Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles.

Authors:  Rongrong Zhu; Ka-Wing Cheng; Gerardo Mackenzie; Liqun Huang; Yu Sun; Gang Xie; Kveta Vrankova; Panayiotis P Constantinides; Basil Rigas
Journal:  Pharm Res       Date:  2012-06-22       Impact factor: 4.200

Review 2.  Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Shigenobu Emoto; Eiji Sunami; Hironori Yamaguchi; Soichiro Ishihara; Joji Kitayama; Toshiaki Watanabe
Journal:  Surg Today       Date:  2014-02-01       Impact factor: 2.549

Review 3.  Pharmaceutical and pharmacological approaches for bioavailability enhancement of etoposide.

Authors:  Ishtiyaq Ahmad Najar; Rakesh Kamal Johri
Journal:  J Biosci       Date:  2014-03       Impact factor: 1.826

4.  Development and evaluation of sustained-release etoposide-loaded poly(ε-caprolactone) implants.

Authors:  Ana Gabriela Reis Solano; Adriana de Fátima Pereira; Flavia Carmo Horta Pinto; Letícia Gonçalves Resende Ferreira; Leandro Augusto de Oliveira Barbosa; Silvia Ligório Fialho; Patrícia Santiago de Oliveira Patricio; Armando da Silva Cunha; Gisele Rodrigues da Silva; Gérson Antônio Pianetti
Journal:  AAPS PharmSciTech       Date:  2013-05-11       Impact factor: 3.246

5.  Toxicogenomics of nanoparticulate delivery of etoposide: potential impact on nanotechnology in retinoblastoma therapy.

Authors:  Moutushy Mitra; Fahima Dilnawaz; Ranjita Misra; Anju Harilal; Rama Shenkar Verma; Sanjeeb K Sahoo; Subramanian Krishnakumar
Journal:  Cancer Nanotechnol       Date:  2010-12-17

Review 6.  Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice.

Authors:  Sabrina Valetti; Simona Mura; Barbara Stella; Patrick Couvreur
Journal:  J Nanobiotechnology       Date:  2013-12-10       Impact factor: 10.435

7.  Different inhibitory effect and mechanism of hydroxyapatite nanoparticles on normal cells and cancer cells in vitro and in vivo.

Authors:  Yingchao Han; Shipu Li; Xianying Cao; Lin Yuan; Youfa Wang; Yixia Yin; Tong Qiu; Honglian Dai; Xinyu Wang
Journal:  Sci Rep       Date:  2014-11-20       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.